{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:20Z","timestamp":1772136320223,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer. In this study, we analyze the role of muscle loss in patients with advanced HCC treated with lenvatinib. This is a retrospective analysis of a real-life cohort of 25 patients with advanced HCC who were treated with lenvatinib from 2018 to March 2021 in Germany. Patients were stratified for loss of skeletal muscle area during the first three months of lenvatinib therapy. Overall survival (OS), progression-free survival (PFS) and toxicity were analyzed for all patients, especially regarding loss of muscle before and during the first three months of therapy with lenvatinib. Three months after beginning of therapy with lenvatinib, a significant reduction of muscle mass was observed in 60% of patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.035). Despite increase of loss of skeletal muscle, patients benefitted from lenvatinib in our cohort of patients in terms of OS and PFS and did not experience increased toxicity. Furthermore, muscle loss was not a negative predictor of survival in the univariate analysis (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.675). Patients with advanced hepatocellular carcinoma experience muscle loss with lenvatinib therapy. However, despite progressive muscle loss, patients benefit from a therapy with lenvatinib in terms of OS and PFS without increased toxicity. However, assessment and prophylaxis of skeletal muscle status should be recommended during a therapy with lenvatinib.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-66766-8","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:03:42Z","timestamp":1727431422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Michael","family":"Praktiknjo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana S.","family":"Pena Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farsaneh","family":"Sadeghlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Welchowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"M\u00f6hring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taotao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Mahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte B.","family":"Monin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"van Beekum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanno","family":"Matthaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Manekeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alois M.","family":"Sprinkart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Luetkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg C.","family":"Kalff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Gonz\u00e1lez-Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"6","key":"66766_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"66766_CR2","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1053\/j.gastro.2022.01.037","volume":"162","author":"M Kanneganti","year":"2022","unstructured":"Kanneganti, M. & Singal, A. G. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease. Gastroenterology 162(6), 1772\u20131774. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.037 (2022).","journal-title":"Gastroenterology"},{"issue":"1","key":"66766_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7(1), 6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"66766_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel, A. & Martinelli, E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann. Oncol. 32(6), 801\u2013805. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014 (2021).","journal-title":"Ann. Oncol."},{"issue":"1","key":"66766_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle, P. R. et al. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69(1), 182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019 (2018).","journal-title":"J. Hepatol."},{"issue":"4","key":"66766_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","volume":"40","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 40(4), 379. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.379 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"10126","key":"66766_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391(10126), 1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1 (2018).","journal-title":"Lancet"},{"issue":"4","key":"66766_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"K Ikeda","year":"2017","unstructured":"Ikeda, K. et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 52(4), 512\u2013519. https:\/\/doi.org\/10.1007\/s00535-016-1263-4 (2017).","journal-title":"J. Gastroenterol."},{"issue":"10","key":"66766_CR9","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.3390\/nu12103101","volume":"12","author":"E Rinninella","year":"2020","unstructured":"Rinninella, E. et al. Skeletal muscle loss during multikinase inhibitors therapy: Molecular pathways, clinical implications, and nutritional challenges. Nutrients 12(10), 3101. https:\/\/doi.org\/10.3390\/nu12103101 (2020).","journal-title":"Nutrients"},{"issue":"10","key":"66766_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/hepr.12774","volume":"46","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa, H. et al. Japan society of hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol. Res. 46(10), 951\u2013963. https:\/\/doi.org\/10.1111\/hepr.12774 (2016).","journal-title":"Hepatol. Res."},{"issue":"4","key":"66766_CR11","doi-asserted-by":"publisher","first-page":"e00025","DOI":"10.14309\/ctg.0000000000000025","volume":"10","author":"M Praktiknjo","year":"2019","unstructured":"Praktiknjo, M. et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Clin. Transl. Gastroenterol. 10(4), e00025. https:\/\/doi.org\/10.14309\/ctg.0000000000000025 (2019).","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"3","key":"66766_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.29602","volume":"67","author":"M Praktiknjo","year":"2018","unstructured":"Praktiknjo, M. et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology 67(3), 1014\u20131026. https:\/\/doi.org\/10.1002\/hep.29602 (2018).","journal-title":"Hepatology"},{"key":"66766_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9, 629\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(08)70153-0 (2008).","journal-title":"Lancet Oncol."},{"key":"66766_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar, S. S., Williams, G. R., Muss, H. B. & Nishijima, T. F. Prognostic value of sarcopenia in adults with solid tumors: A meta-analysis and systematic review. Eur. J. Cancer 57, 58\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030 (2016).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"66766_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3748\/wjg.v28.i4.432","volume":"28","author":"A Perisetti","year":"2022","unstructured":"Perisetti, A. et al. Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions. World J. Gastroenterol. 28(4), 432\u2013448. https:\/\/doi.org\/10.3748\/wjg.v28.i4.432 (2022).","journal-title":"World J. Gastroenterol."},{"key":"66766_CR16","doi-asserted-by":"publisher","first-page":"831005","DOI":"10.3389\/fmed.2022.831005","volume":"9","author":"A Faron","year":"2022","unstructured":"Faron, A. et al. Combination of fat-free muscle index and total spontaneous portosystemic shunt area identifies high-risk cirrhosis patients. Front. Med. (Lausanne) 9, 831005. https:\/\/doi.org\/10.3389\/fmed.2022.831005 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"66766_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jhep.2021.11.006","volume":"76","author":"X Tantai","year":"2022","unstructured":"Tantai, X. et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J. Hepatol. 76(3), 588\u2013599. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.006 (2022).","journal-title":"J. Hepatol."},{"issue":"10","key":"66766_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/MCG.0b013e318293a825","volume":"47","author":"J Meza-Junco","year":"2013","unstructured":"Meza-Junco, J. et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J. Clin. Gastroenterol. 47(10), 861\u2013870. https:\/\/doi.org\/10.1097\/MCG.0b013e318293a825 (2013).","journal-title":"J. Clin. Gastroenterol."},{"issue":"12","key":"66766_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/17474124.2018.1534586","volume":"12","author":"CS Hsu","year":"2018","unstructured":"Hsu, C. S. & Kao, J. H. Sarcopenia and chronic liver diseases. Expert Rev. Gastroenterol. Hepatol. 12(12), 1229\u20131244. https:\/\/doi.org\/10.1080\/17474124.2018.1534586 (2018).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"66766_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00535-020-01711-w","volume":"55","author":"G Marasco","year":"2020","unstructured":"Marasco, G. et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J. Gastroenterol. 55(10), 927\u2013943. https:\/\/doi.org\/10.1007\/s00535-020-01711-w (2020).","journal-title":"J. Gastroenterol."},{"issue":"7","key":"66766_CR21","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/jgh.15336","volume":"36","author":"A Hiraoka","year":"2021","unstructured":"Hiraoka, A. et al. Real-life practice experts for HCC (RELPEC) Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. J. Gastroenterol. Hepatol. 36(7), 1812\u20131819. https:\/\/doi.org\/10.1111\/jgh.15336 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"66766_CR22","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.26355\/eurrev_201911_19583","volume":"23","author":"E Rinninella","year":"2019","unstructured":"Rinninella, E. et al. Minimal impact of lenvatinib (Lenvima\u00ae) on muscle mass in advanced hepatocellular carcinoma and implications for treatment duration. Two cases from the REFLECT study. Eur. Review for Med. Pharmacol. Sci. 23, 10132\u201310138. https:\/\/doi.org\/10.26355\/eurrev_201911_19583 (2019).","journal-title":"Eur. Review for Med. Pharmacol. Sci."},{"issue":"8","key":"66766_CR23","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/cancers12082146","volume":"12","author":"K Endo","year":"2020","unstructured":"Endo, K. et al. Impact of grip strength in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Cancers (Basel) 12(8), 2146. https:\/\/doi.org\/10.3390\/cancers12082146 (2020).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"66766_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000504604","volume":"9","author":"H Uojima","year":"2020","unstructured":"Uojima, H. et al. Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib. Liver Cancer 9(2), 193\u2013206. https:\/\/doi.org\/10.1159\/000504604 (2020).","journal-title":"Liver Cancer"},{"issue":"16","key":"66766_CR25","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.3390\/app10165403","volume":"10","author":"Y Kotoh","year":"2020","unstructured":"Kotoh, Y. et al. Effect of handgrip strength on clinical outcomes of patients with hepatocellular carcinoma treated with lenvatinib. Appl. Sciences. 10(16), 5403. https:\/\/doi.org\/10.3390\/app10165403 (2020).","journal-title":"Appl. Sciences."},{"issue":"5","key":"66766_CR26","doi-asserted-by":"publisher","first-page":"e28680","DOI":"10.1097\/MD.0000000000028680","volume":"101","author":"D Dong","year":"2022","unstructured":"Dong, D. et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib. Medicine (Baltimore) 101(5), e28680. https:\/\/doi.org\/10.1097\/MD.0000000000028680 (2022).","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"66766_CR27","doi-asserted-by":"publisher","first-page":"e0165","DOI":"10.1097\/HC9.0000000000000165","volume":"7","author":"A Surov","year":"2023","unstructured":"Surov, A., Thormann, M. & Hinnerichs, M. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial. Hepatol. Commun. 7(6), e0165. https:\/\/doi.org\/10.1097\/HC9.0000000000000165 (2023).","journal-title":"Hepatol. Commun."},{"issue":"9","key":"66766_CR28","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00268-019-05013-y","volume":"43","author":"Y Kitano","year":"2019","unstructured":"Kitano, Y. & Yamashita, Y. I. Sarcopenia afects systemic and local immune system and impacts postoperative outcome in patients with extrahepatic cholangiocarcinoma. World J. Surg. 43(9), 2271\u20132280. https:\/\/doi.org\/10.1007\/s00268-019-05013-y (2019).","journal-title":"World J. Surg."},{"issue":"5","key":"66766_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.autrev","volume":"17","author":"AM Afzali","year":"2018","unstructured":"Afzali, A. M. et al. Skeletal muscle cells actively shape (auto) immune responses. Autoimmun. Rev. 17(5), 518\u2013529. https:\/\/doi.org\/10.1016\/j.autrev (2018).","journal-title":"Autoimmun. Rev."},{"key":"66766_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ebiom.2019.10.034","volume":"49","author":"C Nelke","year":"2019","unstructured":"Nelke, C. et al. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine 49, 381\u2013388. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.034 (2019).","journal-title":"EBioMedicine"},{"key":"66766_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during frst-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74\u201382. https:\/\/doi.org\/10.1200\/JCO.2014.57.3329 (2015).","journal-title":"J. Clin. Oncol."},{"key":"66766_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clnesp.2022.04.009","volume":"49","author":"C March","year":"2022","unstructured":"March, C. et al. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis. Clin. Nutr. ESPEN 49, 103\u2013113. https:\/\/doi.org\/10.1016\/j.clnesp.2022.04.009 (2022).","journal-title":"Clin. Nutr. ESPEN"},{"issue":"1","key":"66766_CR33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41598-022-27238-z","volume":"13","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis. Sci. Rep. 13(1), 934. https:\/\/doi.org\/10.1038\/s41598-022-27238-z (2023).","journal-title":"Sci. Rep."},{"key":"66766_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000484950","volume":"7","author":"KV Chang","year":"2018","unstructured":"Chang, K. V. et al. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: A systematic review and meta-analysis. Liver Cancer 7, 90\u2013103. https:\/\/doi.org\/10.1159\/000484950 (2018).","journal-title":"Liver Cancer"},{"key":"66766_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/MCG.0b013e318293a825","volume":"47","author":"J Meza-Junco","year":"2013","unstructured":"Meza-Junco, J. et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J. Clin. Gastroenterol. 47, 861\u2013870. https:\/\/doi.org\/10.1097\/MCG.0b013e318293a825 (2013).","journal-title":"J. Clin. Gastroenterol."},{"issue":"1","key":"66766_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21873\/anticanres.15471","volume":"42","author":"N Shimozato","year":"2022","unstructured":"Shimozato, N. et al. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in Japan. Anticancer Res. 42(1), 173\u2013183. https:\/\/doi.org\/10.21873\/anticanres.15471 (2022).","journal-title":"Anticancer Res."},{"issue":"11","key":"66766_CR37","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3390\/cancers13112608","volume":"13","author":"K Tsuchiya","year":"2021","unstructured":"Tsuchiya, K. et al. The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers 13(11), 2608. https:\/\/doi.org\/10.3390\/cancers13112608 (2021).","journal-title":"Cancers"},{"issue":"1","key":"66766_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000512239","volume":"10","author":"MJ Goh","year":"2021","unstructured":"Goh, M. J. et al. Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea. Liver Cancer 10(1), 52\u201362. https:\/\/doi.org\/10.1159\/000512239 (2021).","journal-title":"Liver Cancer"},{"issue":"30","key":"66766_CR39","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.3748\/wjg.v26.i30.4465","volume":"26","author":"DX Wang","year":"2020","unstructured":"Wang, D. X. et al. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J. Gastroenterol. 26(30), 4465\u20134478. https:\/\/doi.org\/10.3748\/wjg.v26.i30.4465 (2020).","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"66766_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/RLI.0000000000000647","volume":"55","author":"S Nowak","year":"2020","unstructured":"Nowak, S., Faron, A. & Luetkens, J. A. Fully automated segmentation of connective tissue compartments for CT-based body composition analysis: A deep learning approach. Invest. Radiol. 55(6), 357\u2013366 (2020).","journal-title":"Invest. Radiol."},{"key":"66766_CR41","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.119.042927","volume":"141","author":"JA Luetkens","year":"2020","unstructured":"Luetkens, J. A. et al. Opportunistic computed tomography imaging for the assessment of fatty muscle fraction predicts outcome in patients undergoing transcatheter aortic valve replacement. Circulation 141, 234\u2013236. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042927 (2020).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66766-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66766-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66766-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:12:39Z","timestamp":1727431959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66766-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66766"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66766-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2771181\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author MG contributed to advisory boards for Roche, Eisai, MSD, BMS, AZ, Lilly and Servier. However, these activities have no potential conflicts of interest with the manuscript.\u00a0The\u00a0other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22146"}}